top of page
搜尋

CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe

作家相片: nuaxia
nuaxia
1天前
讀畢需時 2 分鐘

The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation.


Innovent announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion on 12 November 2026 recommending Zybrivo (sintilimab) in combination with chemotherapy for first-line treatment of eligible adults with non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, regardless of PD-L1 expression.


The recommendation is supported by clinical evidence showing improved progression-free survival compared with chemotherapy alone and represents an important European regulatory milestone for the PD-1-targeting immunotherapy, but the European Commission must still issue its final marketing authorisation decision before the recommendation becomes an EU approval.

Field

Content

Article Type

Approvals

Company

Innovent

Product Brand Name

Zybrivo

Active Ingredient

Sintilimab

Drug Classification

Immune checkpoint inhibitor

Molecular Target

PD-1

Regulatory Authority

European Medicines Agency

Regulatory Committee

Committee for Medicinal Products for Human Use

Regulatory Committee Abbreviation

CHMP

Opinion Date

12 November 2026

Regulatory Outcome

Positive CHMP opinion

Regulatory Recommendation

Marketing authorisation recommended

Final European Commission Approval

Not yet granted according to supplied summary

Regulatory Market

European Union

Therapeutic Area

Oncology

Cancer Type

Non-small cell lung cancer

Histological Subtype

Non-squamous

Treatment Line

First line

Proposed Treatment Regimen

Sintilimab in combination with chemotherapy

Proposed Patient Population

Eligible adults with non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations

EGFR Status Requirement

No EGFR genomic aberrations

ALK Status Requirement

No ALK genomic aberrations

PD-L1 Eligibility

Irrespective of PD-L1 expression

Supporting Clinical Evidence

Clinical trial evidence of improved progression-free survival

Progression-Free Survival Finding

Improvement versus chemotherapy alone

Overall Survival Results

Not specified in supplied summary

Commercial Launch Status

Not yet authorised for launch on the basis of this CHMP opinion

What Happened

The CHMP recommended European marketing authorisation for Zybrivo in a specified first-line lung cancer setting.

Why It Matters

The recommendation moves another immunotherapy option closer to potential availability for eligible European lung cancer patients.

Clinical Significance

Supporting evidence demonstrated improved progression-free survival when sintilimab was combined with chemotherapy.

Regulatory Significance

Represents a positive scientific opinion preceding a potential European Commission marketing authorisation.

Regulatory Clarification

A positive CHMP opinion is not a final European Commission approval.

Key Takeaway

Zybrivo has received a positive CHMP recommendation for first-line non-squamous lung cancer, with the final EU authorisation decision still pending.

What to Watch

European Commission decision, final authorised product information, reimbursement assessments and European commercialisation plans.

Primary Source

European Medicines Agency

Primary Source URL

https://www.ema.europa.eu/en/medicines/human/EPAR/zybrivo

Submitted Source

Innovent announcement

Submitted Source URL

https://www.prnewswire.com/news-releases/innovent-announces-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-first-line-treatment-of-non-squamous-non-small-cell-lung-cancer-302939658.html

Relevant Date

12 November 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

留言

評等為 0(最高為 5 顆星)。
暫無評等

新增評等
bottom of page